The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Lucira Health’s COVID-19 & Flu Test for use in point-of-care settings.

The nucleic acid amplification test (NAAT)/molecular test has been developed for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B viral RNA.

It uses a single anterior nasal swab sample collected from people aged two years and above, who are suspected of having a respiratory viral infection by their healthcare provider, to test for Covid-19 and all its variants of concern as well as Flu A and Flu B.

The PCR Lab-quality test provides positive results in as little as 11 minutes, while a negative result takes 30 minutes.

Lucira Health stated that the combination test leverages the same platform and device design that is used in its FDA-authorised and commercialised Covid-19 test.

The Lucira COVID-19 & Flu Test has shown a similar performance in clinical trials compared to other high-sensitive lab-based PCR assays.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lucira Health president and CEO Erik Engelson said: “Covid-19 and flu viruses can both cause serious illness with similar symptoms, but each has unique prescription treatments that require diagnosis early in the infection to be effective.

“The inaccuracy of antigen Covid-19 tests makes such tests inadequate to use for early differential diagnosis of flu versus Covid-19.

“Clinicians can now facilitate simultaneous rapid testing at a mass scale to get patients on the path to recovery quickly.”

The single-use RT-LAMP test kit is designed to fit in the palm of a hand and runs on two AA batteries.

It also eliminates the need to separately purchase and maintain any reader or instrument.

Additionally, it is claimed to be the first combination test in a pipeline of other multiple assay tests that use the Lucira technology platform to multiplex from a single sample.